LLY Stock: Where Compounding Could Take The Price

LLY Stock: Where Compounding Could Take The Price

At $1,226, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on:

While its cardiometabolic drugs portfolio continues to anchor near-term growth, the company is quietly executing a major pivot. Through acquisitions like AtaiBeckley and Curevo, it is building entirely new platforms. These moves target complex areas like treatment-resistant depression and infectious disease prevention, expanding the company's long-term therapeutic reach.

This expansion is funded by an unprecedented revenue engine. The incretin franchise, led by Mounjaro and Zepbound, is compounding at a staggering rate. This top-line momentum is the primary force creating financial capacity for both new ventures and shareholder returns.

*LTM: Last Twelve Months

How The Math Gets There

Three projections drive the upside number. Revenue compounds at 30% annually over three years, intentionally below today's 50% pace, because the recent acceleration is unlikely to extrapolate cleanly over a 3-year horizon. Net margin eases from 34% to 31% as today's LTM reverts partway toward the 3-year average of 24%. And the multiple has work to do that is not in the company's favor. LLY's P/E already sits at 41.0x, below its 3-year average of 69.1x. The scenario trims it further to 35.7x, because a slower forward growth rate no longer supports even today's multiple.

Put those three together and earnings move from $26.7B to roughly $53.8B, a 101% jump. Apply the lower multiple to that base and the stock lands near $2153.23, only 76% above today. The multiple takes its cut before the earnings work reaches the share price.

Where The Next Wave Of Growth Comes From

The next wave of growth may already be underway, but it is not yet reflected in the financials. The Medicare GLP-1 Bridge program, which launched on July 1, 2026, is a significant catalyst. This program grants insurance coverage to 20 million eligible Americans, opening a vast new patient population.

And what could break it?

A key risk is embedded directly in the success of Zepbound. Management concedes that its high net price, currently sustained by medical exceptions, is temporary. They expect net realized prices to moderate over time as broader formulary and insurance access normalize reimbursement.

If You're Buying LLY At Today's Price

You are paying for steady compounding, not a re-rating and not a margin miracle. The bet is that revenue keeps moving at roughly the projected pace; if it doesn't, the math has nowhere else to turn.

Lilly expects broader volume growth to absorb the lower realized price, though any shortfall in adoption would directly challenge the revenue framework.

Should You Invest In Eli Lilly?

For a different read on LLY, see our recent piece Why Isn't Eli Lilly Stock Trading At The Top Of Its Peer Group?

A careful 3-year case on a single name is still a concentrated bet, as historical volatility across past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book, partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.

If it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV covers that single sector. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.

The Trefis High Quality (HQ) Portfolio combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and a sizing and rebalancing discipline designed to deliver upside without the single-name risk you just read through here.

By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced a benchmark that combines the three major indices - the S&P 500, S&P MidCap, and Russell 2000.